The aim of our study was to assess the percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of the left main coronary artery disease. The study was a prospective, analytical, observational descriptive one, it included a total number of 83 patients, consecutively included in order to avoid bias, for a period of three years between October 2012 and December 2015. The follow-up was performed for 3 years, initially at one month, then at an interval of three to six months. The primary clinical endpoint was mortality of any cause of the patients included in the study. Other main objectives assessed in our study were symptomatic ischemic heart disease manifested with angina pectoris, the need for myocardial revascularization, nonfatal myocardial infarction, and reduction of left ventricular ejection fraction. In patients with LMCAD, we noticed an increase in mortality in patients with PCI vs. CABG, recurrence of angina pectoris, acute myocardial infarction, myocardial revascularization, and depression of the ejection fraction of the left ventricle. In conclusion, the treatment of left main coronary artery disease by using coronary artery bypass grafting is superior to treatment using percutaneous coronary angioplasty.
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial
